ChiCTR2600123594 Adebrelimab Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines ChiCTR2600123594 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 22 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why ChiCTR2600123594 is a hot trial to watch
Non-squamous non-small cell lung cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. ChiCTR2600123594 is notable because it evaluates Adebrelimab in a Phase 3 design sponsored by Hunan Cancer Hospital. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | ChiCTR2600123594 |
| Official title | A multicenter, randomized, open-label, controlled, phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection combined with adebrelimab versus docetaxel in patients with driver gene-negative advanced or metastatic non-squamous non-small cell lung cancer who have progressed or relapsed after prior standard platinum-based chemotherapy. |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Adebrelimab |
| Sponsor | Hunan Cancer Hospital |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
| Endpoint time frame | From the time of informed consent until the subject completes the study |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Adebrelimab in Non-squamous non-small cell lung cancer.
Allocation is not reported, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the time of informed consent until the subject completes the study) — For PFS assessed by BICR, the stratified log-rank test adjusted for randomization stratification factors will be used to compare the statistical difference in PFS between the experimental group and the control group, with p-values calculated. The Kaplan?Meier method will be used to plot survival curves and estimate the median PFS (mPFS) along with its 95% confidence interval (CI) using the Brookmeyer?Crowley method.
- OS (From the time of informed consent until the subject completes the study) — For overall survival (OS), the stratified log?rank test adjusted for randomization stratification factors will be used to compare the statistical difference in OS between the experimental group and the control group, with p?values calculated. The Kaplan?Meier method will be used to plot survival curves and estimate the median OS (mOS) and its 95% confidence interval (CI) using the Brookmeyer?Crowley method. The 12?,
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Adebrelimab is indexed as Monoclonal antibody, with target PDL1, mechanism PDL1 inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Hunan Cancer Hospital did not return an exact normalized organization match in this snapshot. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
ChiCTR2600123594 provides a focused lens on Non-squamous non-small cell lung cancer development. Its value will be determined by whether Adebrelimab can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
